Fox Chase Cancer Center News

PHILADELPHIA (September 17, 2021)—Results from the phase 3 INVICTUS clinical trial show that the drug ripretinib, also known by its brand name Qinlock, provides clinically meaningful improvement in overall median survival for patients with gastrointestinal stromal tumor (GIST) when compared with placebo.

PHILADELPHIA (September 15, 2021)—Fox Chase Cancer Center’s Edna “Eti” Cukierman, PhD, co-director of the Marvin & Concetta Greenberg Pancreatic Cancer Institute, recently published a “Landmark” commentary in the journal Cancer Research that explored the impact of a key study.

PHILADELPHIA (September 13, 2021)—A recent study from Fox Chase Cancer Center has found that in patients treated with radical cystectomy—removal of the bladder—those with cT1 micropapillary bladder cancer had similar or worse oncological outcomes compared with patients with cT2 conventional urothelial carcinoma.

PHILADELPHIA (September 11, 2021)—In a recent study, Fox Chase Cancer Center researchers highlighted immediate cardiopulmonary risks associated with patients undergoing minimally invasive partial nephrectomy or prostatectomy for low-grade, low-stage disease. The study compared these risks with those associated with disease surveillance.

PHILADELPHIA (September 9, 2021)—As thousands of urologists from around the world gather virtually for the American Urological Association 2021 Annual Meeting, 10 Fox Chase Cancer Center faculty and students will present their research on a range of topics.

PHILADELPHIA (September 8, 2021)—Researchers at Fox Chase Cancer Center have identified a molecular circuit that plays a key role in regulating gut immunity. The researchers say the discovery could be a first step in the development of new therapies for colitis, inflammatory bowel disease (IBD), and other disorders.

PHILADELPHIA (September 7, 2021) - Fox Chase Cancer Center is delighted to unite with communities across the country to support the National Ovarian Cancer Coalition (NOCC) for its national Together in Teal event. To donate, participate, or learn more about the Temple Health-Fox Chase Cancer Center team, click here.

PHILADELPHIA (September 6, 2021) – Fox Chase Cancer Center is pleased to announce the hiring of Lu Chen, PhD, who will join the Cancer Signaling and Epigenetics Program and the Cancer Epigenetics Institute (CEI) as an assistant professor.